Randomized angiographic trial of recombinant tissue-type plasminogen activator (alteplase) in myocardial infarction. RAAMI Study Investigators
RJ Carney,
GA Murphy,
TR Brandt,
PJ Daley,
E Pickering,
HJ White,
TJ McDonough,
SK Vermilya,
and
SL Teichman
Department of Cardiology, Mother Frances Heart Institute, Tyler, Texas 75701.
Clot dissolution with restoration of infarct-related artery blood flow is the likely mechanism for the improved prognosis and mortality reduction seen after thrombolytic therapy of acute myocardial infarction. A pilot study has suggested that 100 mg of recombinant tissue-type plasminogen activator (rt-PA) infused over 90 min may lead to higher patency rates than the current standard of 100 mg over 3 h. In this multicenter, randomized, open label trial, 281 patients with acute myocardial infarction receive 100 mg of rt-PA according to either the standard 3-h infusion regimen (an initial 10-mg bolus followed by 50 mg for the 1st h, then 20 mg/h for 2 h) or an accelerated 90-min regimen (15-mg bolus followed by 50 mg over 30 min, then 35 mg over 60 min). All patients also received intravenous heparin and oral aspirin during and after rt-PA infusion. At 60 min after initiation of the rt-PA infusion, the observed angiographic patency rates were 76% (95% confidence intervals 65% to 84%) in the accelerated regimen group and 63% in the control group (52% to 73%, p = 0.03). At 90 min these rates were 81% (73% to 87%) and 77% (68% to 84%), respectively (p = 0.21). Both randomized groups experienced similar rates of recurrent ischemia, reinfarction, angiographic reocclusion, other complications of myocardial infarction (including stroke and death) and bleeding complications.(ABSTRACT TRUNCATED AT 250 WORDS)
This article has been cited by other articles:
|
|
|
|
 
S. G. Goodman, V. Menon, C. P. Cannon, G. Steg, E. M. Ohman, and R. A. Harrington
Acute ST-Segment Elevation Myocardial Infarction: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition)
Chest,
June 1, 2008;
133(6_suppl):
708S - 775S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. Menon, R. A. Harrington, J. S. Hochman, C. P. Cannon, S. D. Goodman, R. G. Wilcox, H. J. Schunemann, and E. M. Ohman
Thrombolysis and Adjunctive Therapy in Acute Myocardial Infarction: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy
Chest,
September 1, 2004;
126(3_suppl):
549S - 575S.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
T. WALLEY, Y. DUNDAR, R. HILL, and R. DICKSON
Superiority and equivalence in thrombolytic drugs: an interpretation
QJM,
February 1, 2003;
96(2):
155 - 160.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. M. Ohman, R. A. Harrington, C. P. Cannon, G. Agnelli, J. A. Cairns, and J.W. Kennedy
Intravenous Thrombolysis in Acute Myocardial Infarction
Chest,
January 1, 2001;
119(2009):
253S - 277S.
[Full Text]
[PDF]
|
|
|
|
|
|
|
E. Garcia, J. Elizaga, N. Perez-Castellano, J. A. Serrano, J. Soriano, M. Abeytua, J. Botas, R. Rubio, E. Lopez de Sa, J. L. Lopez-Sendon, et al.
Primary angioplasty versus systemic thrombolysis in anterior myocardial infarction
J. Am. Coll. Cardiol.,
March 1, 1999;
33(3):
605 - 611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R.J. Simes, E. J. Topol, D. R. Holmes Jr, H. D. White, W. R. Rutsch, A. Vahanian, M. L. Simoons, D. Morris, A. Betriu, R. M. Califf, et al.
Link Between the Angiographic Substudy and Mortality Outcomes in a Large Randomized Trial of Myocardial Reperfusion : Importance of Early and Complete Infarct Artery Reperfusion
Circulation,
April 1, 1995;
91(7):
1923 - 1928.
[Abstract]
[Full Text]
|
|
|
|
|
|
|
R. M. Prewitt, S. Gu, U. Schick, and J. Ducas
Effect of Rate of Administration of Recombinant Tissue Plasminogen Activator on Efficacy of Coronary Thrombolysis
Angiology,
August 1, 1994;
45(8):
687 - 694.
[Abstract]
[PDF]
|
|
|
|
